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TREAT was a recently concluded, and well-powered and
designed, study of anemia treatment in chronic kidney
disease (CKD). Unlike most previous studies of ESA treatment
in nondialysis CKD, TREAT was a placebo-controlled trial.
The placebo group in TREAT provides a unique long-term
view of a conservative approach to anemia management
in nondialysis CKD. The course of mean Hgb levels in
the placebo group ran counter to expectations, increasing
over time. We discuss possible reasons for this, including
a new hypothesis that there may be an erythropoietin
‘honeymoon phase’ similar to that observed in diabetes
mellitus. We propose investigation of this phenomenon
as it could lead to less expensive and safer approaches
to treatment of CKD anemia.
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The recent publication of the Trial to Reduce Cardiovascular
Events with Aranesp Therapy (TREAT) study1 marks a
landmark moment in our understanding of the anemia of
chronic kidney disease (CKD) and its treatment. Despite 20
years of the FDA (Food and Drug Administration)-approved
use of erythropoiesis-stimulating agents (ESAs) for anemia
treatment in CKD, most published studies on the utility of
treatment have been underpowered and, more importantly,
have generally lacked a placebo control. The TREAT study
was designed as a 4000-patient, double-blinded, randomized,
placebo-controlled trial. This rigorous methodology makes it
the most important study published to date on anemia
treatment in CKD. The reported results are fascinating, and
lead to a necessary reconsideration of anemia in CKD and
how treatment should be applied. In particular, the course of
anemia in the placebo group of TREAT raises fundamental
new questions about the natural history of the anemia of CKD.
In this commentary, we will propose the hypothesis that as for
insulin in type 1 diabetes mellitus (another hormone deficiency
state), an erythropoietin honeymoon phase may exist in the
anemia of CKD. Regardless of whether this hypothesis is
subsequently supported or refuted, the ‘natural history’ as
described by the placebo group in TREAT offers interesting
observations with important clinical implications.
The honeymoon phase in type 1 diabetes is a period that
occurs after the initial disease presentation, during which the
disease seems to temporarily become less severe. A recently
proposed definition is, ‘a period when the insulin need is
50% or less of the original insulin dose while maintaining
good metabolic control.’2 The remission that occurs during
the honeymoon phase is usually partial but could also be
complete.2 In the United States, a honeymoon phase occurs
in approximately 42% of patients with newly diagnosed type
1 diabetes mellitus.3 A honeymoon phase in the anemia of
CKD might be operationally defined as a period after the
initial dependence of ESA treatment in which dose require-
ments decline by 50% while hemoglobin (Hgb) is maintained
between 10 and 12 g/dl for a period of 43 months.
THE TREAT PLACEBO GROUP
TREAT included participants with type 2 diabetes mellitus,
estimated glomerular filtration rate of 20–60ml/min, and
Hgb o11 g/dl. Subjects from 623 sites in 24 countries were
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randomized in a 1:1 ratio to treatment with darbepoetin alfa
(Aranesp; Amgen, Thousand Oaks, CA) or placebo. Blinded
Hgb testing was used to guide darbepoetin dosing to a target
Hgb of 13 g/dl. Placebo-treated patients received rescue
therapy with darbepoetin if their Hgb levels fell to o9.0 g/dl,
and subsequently returning to placebo as soon as their Hgb
levels rose to 49.0 g/dl.
The placebo group comprised 2026 patients whose mean
duration of follow-up was 29.1 months. This cohort
obviously represents a group of impressive size with a
significant duration of follow up. Although the placebo group
cannot be considered to truly represent the natural history of
CKD-related anemia, it does represent a cohort with very
conservatively treated anemia. Processes that differed from
the natural history included: (1) the use of darbepoetin
therapy to ‘rescue’ if a patient’s Hgb fell to o9 g/dl, with
immediate termination of treatment as soon as the Hgb was
49 g/dl, (2) the use of both oral and intravenous iron
treatment, (3) blood transfusion for severe anemia, and (4)
the close observation that occurs with research study
participation.
AN ERYTHROPOIETIN ‘HONEYMOON’ PERIOD?
One of the most fascinating findings of the TREAT study was
the Hgb levels observed in the placebo group. The entry
criterion of Hgbo11 g/dl resulted in a mean Hgb at baseline
in the placebo group of 10.4 g/dl. One might have speculated,
a priori, that as the CKD of patients progressed over the years
of observation, the mean Hgb would decline as well. But,
instead of declining, the mean Hgb level rose progressively
over time, reaching a mean Hgb of approximately 11.1 g/dl at
48 months. This relative stability or improvement in mean
Hgb concentration was unexpected and raises questions
about the course of the anemia due to CKD.
Various factors could explain the stability of mean Hgb in
the TREAT placebo group. One hypothesis is that the natural
history of anemia in CKD may be more complex than
previously thought. In classic CKD-related anemia, relative
erythropoietin deficiency results in a failure to maintain
balance between red cell production and red cell loss to
senescence.4–6 Presumably, once anemia develops, it is a
chronic and progressive condition. But this assumption has
not been well tested. In fact, we have often observed that
many patients, after initiating ESA treatment, gradually
require smaller doses with less frequent administration. This
raises the question of whether the underlying anemia may
have improved, whether these patients still require any ESA
therapy, or whether many are initiated on an ESA during a
period of decreased responsiveness to their endogenous
erythropoietin that subsequently resolves. It is unlikely that
many nephrologists test ongoing ESA necessity by a
prolonged challenge of withholding treatment. The TREAT
placebo results would seem to suggest that at least some
patients with mild anemia in CKD may only temporarily
require ESA treatment as the severity of their anemia may
improve but definitely varies over time.
Erythropoietin deficiency typically develops slowly in
CKD.4–6 The deficiency is relative, with erythropoietin levels
appearing normal but lower than expected for the degree of
anemia. Radtke et al.7 measured serum erythropoietin levels
in 135 subjects with CKD and 59 subjects with normal kidney
function. Serum erythropoietin levels were found to be
elevated in patients with CKD compared with those with
normal kidney function. However, the relationship between
serum erythropoietin level and Hgb level varied based on
kidney function. Among those with mild CKD, investigators
found a normal erythropoietin response to anemia in that
lower Hgb levels were associated with higher measures of
serum erythropoietin. With more advanced CKD, serum
erythropoietin levels were found to be inappropriately low
for the degree of anemia present. Among those with a
creatinine clearance of o40ml/min, serum erythropoietin
concentration decreased as creatinine clearance declined,
indicating a parallel loss of renal excretory function and
erythropoietin production capacity. Despite the diminished
erythropoietin response with advanced CKD, some degree of
feedback response to Hgb remains. In the 6 months before
starting dialysis, as anemia worsens, although serum
erythropoietin levels are lower than expected, they do
increase in reaction.7 This was confirmed by Walle et al.,8
who found that erythropoietin levels increased after hemor-
rhage and declined after blood transfusion in dialysis
patients. Taken together, these and other9 studies indicate
that in CKD: (1) levels of serum erythropoietin are generally
higher than in patients without kidney disease, (2) serum
erythropoietin levels increase as Hgb declines in mild-to-
moderate CKD, (3) serum erythropoietin levels fail to
increase sufficiently for the levels of anemia among patients
with creatinine clearance of o40ml/min, and (4) even with
severe CKD, some degree of responsiveness to lower Hgb is
retained, although blunted in magnitude. The state of
erythropoietin production and responsiveness in CKD
suggest that anemia should be fairly mild, or at least
relatively easy to treat. In fact, this is exactly what was found
in the placebo group of the TREAT study.
One facet of erythropoietin production in CKD that is
poorly understood is what happens during an acute illness or
episode of increased inflammation. It is possible that an
intercurrent illness or other event could cause a transient
decline in erythropoietin production and serum concentra-
tion. This could result in a transient period of worsening
anemia, for weeks or months, before the eventual later
development of more severe erythropoietin deficiency, with
sustained anemia and when a true chronic need for ESA
therapy develops. When the patient recovers from the acute
event, Hgb levels would rise, perhaps for an extended period
before more intractable erythropoietin deficiency develops.
This phenomenon might sound familiar, as it is often
observed in another hormone deficiency state, in diabetes
mellitus—the so-called ‘honeymoon phase.’10 Given this,
it is possible that practically or physiologically a similar
‘honeymoon phase’ may occur in some or all patients with
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CKD-related anemia (Figure 1). This phenomenon might be
explained by the recognition of anemia and the initiation of
ESAs in two distinct groups of patients: (1) those with a
transient hyporesponsiveness because of a recognized or
unrecognized physiologic stressor and (2) those with later-
stage erythropoietin deficiency. Although the latter group
may require continued dosing of ESA, the former may be able
to be treated more as the placebo group in TREAT: with
conservative temporary interventions. Further analysis of the
placebo group will help to better understand the plausibility
of this phenomenon.
If an erythropoietin honeymoon phase exists in some or
all CKD patients, it raises interesting questions regarding how
ESA therapy should be administered. In actual clinical
practice, the development of anemia usually leads to
initiation of ESA therapy in many patients if Hgb levels
declined to o10 or 11 g/dl. Currently, most patients with
CKD anemia are probably treated to a target Hgb range of
10–12 g/dl. After the acute illness, when erythropoietin levels
rose (the honeymoon phase), Hgb levels could increase in
both the presence and absence of ESA therapy. For patients
who had ESA dosing initiated, the increase in Hgb might
result in reduction in ESA dose or increase in the interval
between doses. Many patients may continue on low doses of
ESA treatment indefinitely. The question that this hypothesis
raises is whether these low doses are necessary. This is
speculative, and additional information is required to truly
understand how ESA therapy interacts with the natural
history of CKD-related anemia. But without knowing the
mechanisms, the TREAT study placebo results are clear;
that is, conservatively managed CKD anemia can be quite
successful. Although this could be explained by informative
censoring as follow-up lengthened, the possibility that it
could be related to a more complicated physiologic
process should be evaluated. Regardless, as we seek to
assimilate the results of the recent major anemia trials
into practice, this represents an interesting treatment strategy
of watchful waiting or brief ESA rescue therapy, which might
be an appropriate start to nondialysis CKD anemia
treatment.
Beyond a hypothesized erythropoietin honeymoon phase,
there are certainly other factors that could explain the TREAT
placebo group’s Hgb stability/improvement. First, 46% of the
placebo group required at least temporary ‘rescue’ treatment
with darbepoetin. It is possible that ‘rescue’ treatment
partially explains the placebo group’s Hgb stability. Second,
there were more blood transfusions in the placebo (24.5%)
compared with the treatment group (14.8%). As transfusion
is generally reserved for severe anemia, and as the mean study
follow-up was 42 years in most patients (and 4 years in
others), the transient effect of transfusion for severe anemia is
not likely to explain a rise in Hgb but rather a failure to fall.
Third, being in a monitored research study with periodic iron
testing, it is likely that placebo patients received more iron
treatment than they would have before study entry.
Intravenous iron treatment was administered in the placebo
group, at some point, in 20.4% of patients (the study
publication did not specify the duration or dosage of
treatment). Oral iron treatment, although of unclear benefit,
was increased from 42.7% at baseline to 68.6% during the
study. This somewhat greater use of iron treatment might
partially explain the stability in mean Hgb. Fourth, the
apparent Hgb rise may reflect a survivor effect, in which
participants with the lowest Hgb levels experience a higher
mortality rate, and hence as time progresses, the mean Hgb is
increased in the surviving group.
In conclusion, a honeymoon phase after ESA initiation
may exist in CKD-related anemia similar to that what is
observed in diabetes mellitus. Further research on this
phenomenon (1) will lead to a greater understanding of the
course of CKD anemia, (2) might change the way treatment
with ESAs is used, and (3) may lead to a more complete
understanding of the relationship between illness and
erythropoietin biology. To the extent that an erythropoietin
honeymoon phase exists, it would suggest, as found in the
TREAT study’s placebo group, that watchful waiting and
delaying ESA treatment or transient ESA rescue therapy while
allowing the patient’s Hgb level to gradually rise on its own
could be a cost-effective, convenient, and safe approach for
many patients.
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Figure 1 | The stability and increase in mean hemoglobin
(Hgb) in the placebo group of the Trial to Reduce
Cardiovascular Events with Aranesp Therapy (TREAT) study
suggest the possibility that a ‘honeymoon phase’ could exist
in some patients with the anemia of chronic kidney disease
(CKD). With CKD, serum erythropoietin levels tend to be normal,
but lower than expected for patients with reduced Hgb levels. It
can be hypothesized that an acute event such as infection could
result in a more abrupt, transient, decline in serum erythropoietin
levels, followed by worsening of anemia. As the acute event
abates, serum erythropoietin levels could temporarily recover to
previous levels, and Hgb may improve as well. Eventually, over
time, however, as CKD progresses, a more severe deficiency of
erythropoietin could develop, resulting in protracted anemia
requiring chronic erythropoiesis-stimulating agent (ESA) therapy.
The intervening recovery period for serum erythropoietin and
Hgb would be analogous to the ‘honeymoon phase’ sometimes
observed in another hormone deficiency state, diabetes mellitus.
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